Keith Kaye

Combination Antibiotic Therapy for Pseudomonas VAP (CombAT Pseudo VAP): A Pragmatic Trial

National Institute of Allergy and Infectious Diseases · U01

PI · $1.5M · Northwestern University

Pharmacology of Intrathecal/Intraventricular Polymyxins: A Systems-Based Approach

National Institute of Allergy and Infectious Diseases · R01

PI · $344.7K · University of Southern California

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection

Agency for Healthcare Research and Quality · R01

Contact PI · $1.5M · University of Michigan at Ann Arbor

Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance

National Institute of Allergy and Infectious Diseases · N01

Contact PI · $11.1M · University of Michigan at Ann Arbor

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection

Principal investigator · Completed

University of Michigan

Optimizing Clinical Use of Polymyxin B

Principal investigator · Completed

Rutgers, The State University of New Jersey

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

Principal investigator · Completed · Phase 3

Melinta Therapeutics, Inc.

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Principal investigator · Completed · Phase 3

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)